Wockhardt Ltd's Turnaround: Soaring Profits and Revenue Spike

Pharmaceuticals firm Wockhardt Ltd reported a significant recovery in Q4 2026, with a net profit of Rs 164 crore compared to a Rs 45 crore loss in the same period last year. The company's revenue increased to Rs 965 crore, highlighting a strong financial turnaround following a challenging fiscal year.

In a remarkable turnaround, pharmaceuticals giant Wockhardt Ltd has reported a consolidated net profit of Rs 164 crore for the fourth quarter ending March 31, 2026. This impressive recovery stands in stark contrast to the Rs 45 crore loss recorded in the corresponding quarter of the previous fiscal year.

Wockhardt's consolidated revenue surged to Rs 965 crore, up from Rs 743 crore a year ago. The company indicated that total expenses for the quarter rose to Rs 843 crore, compared to Rs 780 crore in the same period last year, signaling a robust operational expansion.

For the complete fiscal year of FY26, the company recorded a net profit of Rs 199 crore, reversing a consolidated net loss of Rs 57 crore in FY25. Revenue from operations also saw an upward trend, reaching Rs 3,373 crore against Rs 3,012 crore in FY25, marking a sustained growth trajectory.